NovaBridge Subsidiary Visara Licenses Exclusive Global Rights for New Ophthalmology Therapy

Key Facts

1Visara, a subsidiary of NovaBridge Biosciences, secured exclusive worldwide rights to develop and commercialize HT006.2.2 for neurotrophic keratitis.

Visara, a majority-owned subsidiary of NovaBridge Biosciences, secured exclusive worldwide rights to develop and commercialize the drug HT006.2.2. Reuters reported that the licensing agreement with Wuhan Hiteck Biological Pharma focuses on a nerve growth factor therapy, designated as VIS-102, for the treatment of neurotrophic keratitis.

NBP closed at $1.32 on October 12, 2026, prior to the announcement of this pipeline expansion into ocular surface diseases. The deal aims to provide more convenient treatment options, supported by Phase 1b clinical data which indicated positive corneal healing results in study subjects.